Breaking News
February 18, 2019 - How Inactivity and Junk Food Can Harm Your Brain
February 18, 2019 - Diabetes tops common conditions for frequent geriatric emergency patients
February 18, 2019 - Longer-lived sperm produces offspring with healthier lifespans
February 18, 2019 - New dental adhesive prevents tooth decay around orthodontic brackets
February 18, 2019 - New eHealth tool shows potential to improve quality of asthma care
February 18, 2019 - New Australian initiative helps emergency clinicians to improve patient care
February 17, 2019 - Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
February 17, 2019 - Researchers identify faulty ‘brake’ that interferes with heart muscle’s ability to contract and relax
February 17, 2019 - Support from trusted adults can reduce risk of dying in suicidal teens, finds study
February 17, 2019 - Heart attack awareness improved since 2008
February 17, 2019 - Exercise gives a better brain boost to older men than women
February 17, 2019 - New research disproves previous assumptions of how looks influence personality
February 17, 2019 - Cannabis use as a teenager linked to depression later in life
February 17, 2019 - Sinks by Toilets in ICU Patient Rooms Harbor Harmful Bacteria
February 17, 2019 - Cancer cells’ plasticity makes them harder to stop
February 17, 2019 - Young cannabis users have increased risk of depression and suicidal behavior
February 17, 2019 - Tasmanian Devils Likely to Survive Cancer Scourge
February 17, 2019 - Neoadjuvant PD-1 blockade seems effective in glioblastoma
February 17, 2019 - Personal, social factors play role in enabling sustainable return to work after ill health
February 17, 2019 - Mouse studies show ‘inhibition’ theory of autism wrong
February 17, 2019 - Study shows how neuroactive steroids inhibit activity of pro-inflammatory proteins
February 17, 2019 - Use of liver grafts from older donors decreased despite better outcomes in recipients
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - Promising drug developed to rejuvenate muscle cells
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
New treatment regimen boosts survival for young adults and children with T-cell malignancies

New treatment regimen boosts survival for young adults and children with T-cell malignancies

image_pdfDownload PDFimage_print

ASCO Perspective

“As oncologists, we are constantly striving for better care and outcomes for our patients, even in cancers where survival rates are relatively high compared with others. We now know it’s possible to significantly boost survival in children and young adults with rare forms of leukemia and lymphoma, without introducing additional harsh side effects that can impair their quality of life,” said ASCO President Bruce E. Johnson, MD, FASCO.

In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90% of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84% were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.

The addition of nelarabine (Arranon) to standard chemotherapy provided further benefit for the group of patients with moderate or high risk of T-ALL recurrence — at four years 89% of those who received nelarabine were leukemia-free vs. 83% of those who did not. The study will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.

“T-cell ALL is a disease that requires the use of a very intense and complex chemotherapy regimen. Historically, about 80% of people live at least four years after being treated for their disease, but we felt we could and must do better,” said lead study author Kimberly Dunsmore, MD, professor, Virginia Tech Carilion School of Medicine in Roanoke. “Our trial shows that we could further increase survival rates by about 10%, which is very encouraging.”

About the Study

The trial, begun in 2007, enrolled patients 1-30 years of age with either T-ALL (94% of trial participants) or T-LL (6% of participants). With 1,895 patients, this is the largest randomized clinical trial ever performed in these diseases.

The trial had four arms, with all patients receiving the standard, complex, multi-drug chemotherapy regimen known as COG augmented Berlin-Frankfurt-Munster (aBFM) chemotherapy. In addition to receiving aBFM, patients were randomly assigned to also receive either high-dose methotrexate (a chemotherapy) in a hospital or escalating dose methotrexate (a regimen that starts with low doses of methotrexate, gradually increased over time) in an outpatient setting.

The group of patients with moderate or high risk of cancer recurrence were also randomly assigned to receive or not receive nelarabine, in addition to chemotherapy, and cranial radiation (to prevent or treat brain metastases).

Nelarabine was approved in 2005 by the FDA for the treatment of people with T-ALL and T-LL that had progressed after at least two chemotherapy regimens. Unlike the trials that led to the FDA approval, nelarabine was tested in newly diagnosed patients in this trial.

Key Findings

  • -Overall, 90.2% of patients treated in this trial lived at least four years, and 84.3% had no sign of cancer at four years.

    -In the group of patients with T-ALL who had increased risk of recurrence, 88.9% of those who received nelarabine were leukemia-free at four years compared to 83.3% of those not treated with nelarabine.

    -While patients with T-LL did not benefit from the addition of nelarabine, more than 85% lived for four years without signs of disease.

    -Contrary to results from previous, smaller trials, patients with T-ALL who received escalating doses of methotrexate did better than those who received high-dose methotrexate (four-year disease-free survival with escalating dose was 89.8% vs. 78% with high-dose).

    -Among T-ALL patients randomly assigned to receive both nelarabine and escalating doses of methotrexate, 92.2% were leukemia-free at four years.

    -Patients who did not have cancer remission following the initial (induction) phase of chemotherapy were assigned to receive high-dose methotrexate and nelarabine; 54.8% of survived four years without signs of the disease. This is a significant improvement, as historically only about 20% of people with T-ALL who did not experience cancer remission lived another three years, according to the authors.

Next Steps

Most doctors are moving to decreasing the use of cranial radiation for T-cell leukemia as late side effects can occur after cranial radiation. Late side effects include changes in cognitive abilities, learning disabilities, neuroendocrine changes, and development of secondary malignancy. The next step will be for clinicians to examine the implications and benefits that may accrue when using nelarabine in chemotherapy protocols without cranial radiation.

Source:

https://www.asco.org/about-asco/press-center/news-releases/new-regimens-improve-survival-children-and-young-adults-t-cell

Tagged with:

About author

Related Articles